NuCana plc (NCNA)

GB — Healthcare Sector
Peers:   EFTR  VIRI  ZURA  NAVB  ZVSA  CDTX  SLN  APLT  CTMX  CELL  RANI  VINC  TNYA  CRVS  ALXO  MREO  ABOS  DAWN  INZY  GRTX 

Automate Your Wheel Strategy on NCNA

With Tiblio's Option Bot, you can configure your own wheel strategy including NCNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NCNA
  • Rev/Share 0.0
  • Book/Share 0.0841
  • PB 0.021
  • Debt/Equity 0.0319
  • CurrentRatio 1.4153
  • ROIC -3.1225

 

  • MktCap 10705.473
  • FreeCF/Share -0.2741
  • PFCF -0.0006
  • PE -0.0066
  • Debt/Assets 0.0129
  • DivYield 0
  • ROE -3.136

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade NCNA William Blair Outperform Market Perform -- -- Aug. 30, 2024

News

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
NCNA
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.

Read More
image for news Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

About NuCana plc (NCNA)

  • IPO Date 2017-09-28
  • Website https://www.nucana.com
  • Industry Biotechnology
  • CEO Mr. Hugh Stephen Griffith
  • Employees 20
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.